ArticleCancers2023

Lenvatinib or Sorafenib Treatment Causing a Decrease in Skeletal Muscle Mass, an Independent Prognostic Factor in Hepatocellular Carcinoma: A Survival Analysis Using Time-Varying Covariates.

Kenji Imai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.